Early rhythm control in patients with atrial fibrillation and cancer: a subgroup analysis of the EAST-AFNET 4 trial
Europace · 01.10.2026 · 28 (10)
DOI: 10.1093/europace/euag269 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Europace, online erschienen am 18.09.2026. Verfasst von Djemail Ismaili und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart and Vascular Center Hamburg, Martinistraße 52, 20251 Hamburg, Germany. Hauptthemen laut MEDLINE: Anti-Arrhythmia Agents, Atrial Fibrillation, Heart Rate, Neoplasms. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Heart Foundation/German Foundation of Heart Research, German Ministry of Education and Research, German Centre for Cardiovascular Research.
Abstract (Originalsprache)
Aims
Early rhythm-control improves cardiovascular outcomes in patients with atrial fibrillation (AF). Its effectiveness in patients with cancer is unclear. This study evaluated the effects of cancer history on early rhythm control in the EAST-AFNET 4 trial. Methods and results This secondary analysis of EAST-AFNET 4 compared patients with and without a history of cancer, including active cancer and cancer in remission. Outcomes included the primary outcome, a composite of cardiovascular death, stroke, or hospitalization for worsening heart failure or acute coronary syndrome; the safety outcome, a composite of death, stroke, and serious adverse events related to rhythm control; and rhythm at 24 months. Cancer history was available in 2779 of 2789 patients (99.6%). Cancer history was present in 216 of 2779 (7.8%; 19 with active cancer; mean age, 73 years; 95 [44%] women; mean CHA2DS2-VASc score, 3.5). During a follow-up of 8.6 years, early rhythm control reduced the primary outcome in patients with and without a history of cancer (Pinteraction = 0.23) with high rates of sinus rhythm at 24 months (cancer: 84.9%, without cancer: 81.8%; Pinteraction = 0.60). In patients with a cancer history, there was a signal for more safety outcomes with early rhythm control [early rhythm control 36/116 (31%) patients with event, 22 deaths; usual care 20/100 (20%) patients with event, 18 deaths; Pinteraction = 0.055].
Conclusion
Early rhythm control therapy appears effective in patients with AF and a history of cancer but may be less safe than in patients without cancer, in this hypothesis-generating analysis. This could be a play of chance but warrants further research into the safety and efficacy of rhythm control therapy in patients with a cancer history. Trial Registration ClinicalTrials.gov Identifier: NCT01288352
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University Heart and Vascular Center Hamburg, Martinistraße 52, 20251 Hamburg, Germany.
- German Center for Cardiovascular Research (DZHK), Partner Site North, Martinistraße 52, 20251 Hamburg, Germany.
- Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Department of Cardiology and Intensive Care Medicine, St. Vincenz Hospital, Paderborn, Germany.
- Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.
- MAESTRIA Consortium at AFNET, Münster, Germany.
ORCID-Profile: Djemail Ismaili, Anna Suling, Andreas Goette, Günter Breithardt, A John Camm, Harry Crijns, Lars Eckardt, Arif Elvan, Larissa Fabritz, Isabelle van Gelder, Hein Heidbuchel, Josef Kautzner, Marc Lemoine, G André Ng, Renate B Schnabel, Sakis Themistoclakis, Panos Vardas, Karl Wegscheider, Stephan Willems, Antonia Zapf, Andreas Metzner, Andreas Rillig, Paulus Kirchhof
Förderung
- German Heart Foundation/German Foundation of Heart Research
- German Ministry of Education and Research
- German Centre for Cardiovascular Research
- AFNET (Atrial Fibrillation Network)
- European Heart Rhythm Association (EHRA)
- St. Jude Medical-Abbott
- Sanofi
- German Heart Foundation
Zitieren
APA
Ismaili, D., Suling, A., Borof, K., Goette, A., Breithardt, G., Camm, A. J., Crijns, H., Eckardt, L., Elvan, A., Fabritz, L., van Gelder, I., Gulizia, M., Haegeli, L., Heidbuchel, H., Kautzner, J., Lemoine, M., Ng, G. A., Schnabel, R. B., Szumowski, L., …, & Kirchhof, P. (2026). Early rhythm control in patients with atrial fibrillation and cancer: a subgroup analysis of the EAST-AFNET 4 trial. Europace, 28(10). https://doi.org/10.1093/europace/euag269
Vancouver
Ismaili D, Suling A, Borof K, Goette A, Breithardt G, Camm AJ, et al. Early rhythm control in patients with atrial fibrillation and cancer: a subgroup analysis of the EAST-AFNET 4 trial. Europace. 2026;28(10). doi:10.1093/europace/euag269
BibTeX
@article{Ismaili2026,
author = {Ismaili, Djemail and Suling, Anna and Borof, Katrin and Goette, Andreas and Breithardt, Günter and Camm, A John and Crijns, Harry and Eckardt, Lars and Elvan, Arif and Fabritz, Larissa and van Gelder, Isabelle and Gulizia, Michele and Haegeli, Laurent and Heidbuchel, Hein and Kautzner, Josef and Lemoine, Marc and Ng, G André and Schnabel, Renate B and Szumowski, Lukasz and Themistoclakis, Sakis and Vardas, Panos and Wegscheider, Karl and Willems, Stephan and Zapf, Antonia and Metzner, Andreas and Rillig, Andreas and Kirchhof, Paulus},
title = {Early rhythm control in patients with atrial fibrillation and cancer: a subgroup analysis of the EAST-AFNET 4 trial},
journal = {Europace},
year = {2026},
volume = {28},
number = {10},
doi = {10.1093/europace/euag269}
}
EUVIMED